Treatment of IgA nephropathy

Seminars in Nephrology

Volumn 20, Issue 3, 2000, Pages 277-285

  Julian, Bruce A ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FISH OIL; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

GLOMERULONEPHRITIS; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; NEPHROSIS; PRIORITY JOURNAL; REVIEW; TONSILLECTOMY; TREATMENT INDICATION; TREATMENT PLANNING;

CLINICAL TRIALS; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 0034116482     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Berger J, Hinglais N: Les depots intercapillaries d'IgA-IgG. J Urol Nephrol. 74:694-695, 1968
2. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 245:709-727, 1987
3. Levy M, Berger J: Worldwide perspective of IgA nephropathy. Am J Kidney Dis 12:340-347, 1988
4. Galla JH: IgA nephropathy. Kidney Int 47:377-387, 1995
5. Jennette JC: The immunohistology of IgA nephropathy. Am J Kidney Dis 12:348-352, 1988
6. Chauveau D, Droz D: Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 104:1-5, 1993
7. Yoshikawa N, lijima K, Matsuyama S, et al: Repeat renal biopsy in children with IgA nephropathy. Clin Nephrol 33:160-167, 1990
8. Koyama A, Igarashi M, Kobayashi M, et al: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Group on progressive renal diseases. Am J Kidney Dis 4:526-532, 1997
9. Schena FP, D'Altri C, Cerullo G, et al: Angiotensin converting enzyme (ACE) gene polymorphism and IgA nephropathy (IgAN): A further study and a meta-analysis review. J Am Soc Nephrol 10:88A, 1999 (abstr)
10. Schmidt S, Ritz E: Genetic factors in IgA nephropathy. Ann Med Interne 150:86-90, 1999
11. Coppo R: Polymorphism of a-adducin and angiotensin converting enzyme (ACE) in normotensive and proteinuric young IgA nephropathy patients (IgAN). J Am Soc Nephrol 10:158A, 1999 (abstr)
12. Hashizume K, Hiki Y, Tateno S, et al: Correlation between long-term prognosis and angiotensin converting enzyme (ACE) gene polymorphism in IgA nephropathy. J Am Soc Nephrol 10:102A, 1999 (abstr)
13. Julian B, Tomano M, Novak J, et al: Progress in the pathogenesis of IgA nephropathy. Adv Nephrol 29:53-72, 1999
14. Cheng IK, Chan PC, Chan MK: The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 5:241-246, 1990
15. Hotta O, Miyazaki M, Furuta T, et al: Resolution of IgA nephropathy following steroid semi-pulse therapy combined with tonsillectomy: A repeat biopsy study. J Am Soc Nephrol 10:104A, 1999 (abstr)
16. Yoshikawa N, Hiroshi I, Sakai T, et al: A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10:101-109, 1999
17. Kincaid-Smith P: Treatment of mesangial immunoglobulin IgA glomerulonephritis. Semin Nephrol 19:166-172, 1999
18. Nolin L, Courteau M: Management of IgA nephropathy: Evidence-based recommendations. Kidney Int 55:S55-S62, 1999 (suppl 70)
19. Schiele J, Rainer N, Julian B A, et al: Treatment of immunoglobulin A nephropathy. Ann Med Interne 150:127-136, 1999
20. Remuzzi A, Perico N, Sangalli F, et al: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276:F457-F466, 1999
21. Morrissey JJ, Klahr S: Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 52:926-933, 1997
22. Duque N, Gomez-Guerrero C, Egido J: Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 159:3474-3482, 1997
23. Ichikawa I: Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 50:684-692, 1996
24. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-254, 1994
25. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1459-1462, 1993
26. Giatras I, Lau J, Levey AS: Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 127:337-345, 1997
27. GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
28. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
29. Maschio G, Cagnoli L, Slaroni F, et al: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomised, placebo-controlled study. Nephrol Dial Transplant 9:265-269, 1994
30. Hashizume K, Sano T, Kokubo T, et al: A randomized, prospective, controlled study of effect of angiotensin-converting enzyme inhibition in IgA nephropathy patients. 8th International IgA Nephropathy Symposium Program Book. 51, 1998 (abstr)
31. Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
32. Perico N, Remuzzi A, Sangalli F, et al: The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9:2308-2317, 1998
33. Locatelli F, Pozzi C, Del Vecchio L, et al: New therapeutic approaches in primary IgA nephropathy. Adv Nephrol 20:73-91, 1999
34. Pozzi C, Bolasco P, Fogazzi G, et al: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353:883-862, 1999
35. Pozzi C, Del Vecchio L, Andrulli S, et al: Steroid therapy in IgA nephropathy. J Am Soc Nephrol 10:86A, 1999 (abstr)
36. Grande JP, Donadio, Jr JV: Dietary fish oil supplementation in IgA nephropathy: A therapy in search of a mechanism? Nutrition 2:240-242, 1998
37. Hamazaki T, Tateno S, Shishido H: Eicosapentaenoic acid and IgA nephropathy. Lancet 1:1017-1018, 1984
38. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with eicosapentanoic acid (EPA: a two-year prospective trial). Clin Nephrol 31:128-131, 1989
39. Pettersson EE, Rekola S, Berglund L, et al: Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol 41: 183-190, 1994
40. Donadio, Jr JV, Bergstralh EJ, Offord KP, et al: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331:1194-1199, 1994
41. Donadio, Jr JV, Grande JP, Bergstralh EJ, et al: The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 10:1772-1777, 1999
42. Dillon JJ: Fish oil therapy for IgA nephropathy: Efficacy and interstudy variability. J Am Soc Nephrol 8:1739-1744, 1997
43. Stangou M, Alexopoulos E, Diamantopoulou D, et al: The effect of fish-oil in human IgA nephropathy (IgAN). J Am Soc Nephrol 10:115A, 1999 (abstr)
44. Andrassy K, Waldherr R, Sis J, et al: ANCA positive disease and IgA-nephropathy: Association or coincidence? 8th International IgA Nephropathy Symposium program book. 16, 1998 (abstr)
45. Harper L, Howie A, Adu D: Treatment of IgA nephropathy with immunosuppressants. 8th International IgA Nephropathy Symposium program book. 63, 1998 (abstr)
46. Akagi H, Nishizaki K, Hattori K, et al: Prognosis of tonsillectomy in patients with IgA nephropathy. Acta Otolaryngol 540:64-66, 1999 (suppl)
47. Barta J, Kovacs T, Fazekas A, et al: Does tonsillectomy cause any change in long-term course of IgA nephropathy? Orv Hetil 137:2903-2906, 1996
48. Tamura S, Masuda Y, Inokuchi I, et al: Effect of and indication for tonsillectomy in IgA nephropathy. Acta Otolaryngol 508:23-28, 1993 (suppl)
49. Sanai A, Kudoh F: Effects of tonsillectomy in children with IgA nephropathy, purpura nephritis, or other chronic glomerulonephritides. Acta Otolaryngol 523:172-174, 1996 (suppl)
50. Tomioka S, Miyoshi K, Tabata K, et al: Clinical study of chronic tonsillitis with IgA nephropathy treated by tonsillectomy. Acta Otolaryngol 523:175-177, 1996 (suppl)
51. Rasche FM, Schwarz A, Keller F: Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 51:147-152, 1999
52. Allison AC, Kowalski WJ, Muller CJ, et al: Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25:67-70, 1993
53. Nowack R, Birck R, van der Woude FJ: Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349:774, 1997
54. Chen XM, Zhang YP, Qui Q, et al: Short-term effects of mycophenolate mofetil on IgA nephropathy. J Am Soc Nephrol 10:69A, 1999 (abstr)
55. Briggs WA, Choi MJ, Scheel, Jr PJ: Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213-217, 1998
56. Clarkson AR, Woodroffe AJ, Bannister KM, et al: Therapy in IgA nephropathy. Contrib Nephrol 104:189-197, 1993
57. Chabova V, Tesar V, Zabka J, et al: Long term treatment of IgA nephropathy with cyclosporin. 8th International IgA Nephropathy Symposium program book 58, 1998 (abstr)
58. Buemi M, Allegra A, Corica F, et al: Effect of fluvastatin on proteinuria in patients with IgA nephropathy. J Am Soc Nephrol 10:69A, 1999 (abstr)
59. Berger J: Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis 12:371-372, 1988
60. Floege J, Burg M, Kliem V: Recurrent IgA nephropathy after kidney transplantation: not a benign condition. Nephrol Dial Transplant 13:1933-1935, 1998
61. Camilleri B, Feehally J, Harden PN: Recurrent crescentic IgA nephropathy post-transplantation: Response to intensive immunosuppression. J Am Soc Nephrol 10:754A, 1999 (abstr)
62. Frohnert PP, Donadio, Jr JV, Velosa JA, et al: The fate of renal transplants in patients with IgA nephropathy. Clin Nephrol 11:127-133, 1997
63. Freese P, Svalander C, Norden G, et al: Clinical risk factors for recurrence of IgA nephropathy. Clin Transplantation 13:313-317, 1999
64. Schwarz A, Krause PH, Offermann G, et al: Recurrent and de novo renal disease after kidney transplantation with or without cyclosporin. Am J Kidney Dis 17:524-531, 1991
65. Julian BA, Said M, Barker CV: Allograft loss in IgA nephropathy. J Am Soc Nephrol 9:91 A, 1998 (abstr)